Norliqva (amlodipine) is filed as Dihydropyridine Calcium Channel Blocker [EPC]. The sections below restate public label fields stored for this profile.
Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: * Hypertension ( 1.1 ) • Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. * Coronary Artery Disease ( 1.2 ) • Chronic Stable Angina • Vasospastic Angina (Prinzmetal's or Variant Angina) • Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following: Exertional Angina: In patients with exertional angina, amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise. Vasospastic Angina: Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro . This inhibition of coronary spasm is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's or variant) angina.
Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely. ( 5.1 ) • Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive coronary artery disease. ( 5.2 ) • Titrate slowly in patients with severe hepatic impairment. ( 5.3 )
Amlodipine besylate tablets are contraindicated in patients with known sensitivity to amlodipine.
Reflected in the table below (Common)
Most common adverse reaction to amlodipine is edema which occurred in a dose related manner. Other adverse experiences not dose related but reported with an incidence >1.0% are fatigue, nausea, abdominal pain, and somnolence. (6) To report SUSPECTED ADVERSE REACTIONS, contact Ascend Laboratories, LLC at 1-877-272-7901 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. ( 2.1 ) Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily. ( 2.1 ) Pediatric starting dose: 2.5 mg to 5 mg once daily. ( 2.2 ) Important Limitation: Doses in excess of 5 mg daily have not been studied in pediatric patients. ( 2.2 )
Do not exceed doses greater than 20 mg daily of simvastatin. (7.2)
According to its FDA label, Norliqva (amlodipine) is approved for: Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: * Hypertension ( 1.1 ) • Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower… For medical advice, please talk to your prescriber or pharmacist.
Norliqva (amlodipine) belongs to the Dihydropyridine Calcium Channel Blocker [EPC] class of medications.
The FDA label lists Norliqva (amlodipine) as: Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely. ( 5.1 ) • Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive coronary artery disease. ( 5.2 ) • Titrate slowly in patients with severe hepatic impairment. ( 5.3 ); oral route. Available strengths and packaging vary by manufacturer.
Yes. A generic version of Norliqva (amlodipine) is available in the U.S. Ask your pharmacist about substitution.
Our ingest of the FDA label for Norliqva (amlodipine) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
The FDA Enforcement Report does not show an active/ongoing recall for Norliqva (amlodipine) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Norliqva (amlodipine) as 2007-07-12.
The FDA label lists CMP Pharma, Inc. as a labeler/manufacturer of Norliqva (amlodipine). Multiple firms may market generics of the same molecule.
The FDA label states: "Product: 50090-7955 NDC: 50090-7955-1 90 TABLET in a BOTTLE NDC: 50090-7955-2 30 TABLET in a BOTTLE" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…